Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02295865 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT02295865 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 62 participants.
The verdict
NCT02295865, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).
Interventions
- DRUG Placebo
- DRUG JNJ-38518168 3 mg
- DRUG JNJ-38518168 30 mg
- DRUG JNJ-38518168 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2016-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02295865
The ClinicalTrials.gov registry entry for NCT02295865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02295865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02295865 about?
NCT02295865 is a clinical study titled "A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis". The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).
What is the current status of trial NCT02295865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2014-11-17. Estimated completion is 2016-03-11.
What interventions are being tested in trial NCT02295865?
The interventions under investigation include: Placebo (DRUG), JNJ-38518168 3 mg (DRUG), JNJ-38518168 30 mg (DRUG), JNJ-38518168 60 mg (DRUG).
Who is sponsoring clinical trial NCT02295865?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.